Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Lung cancer diagnosis from proteomic analysis of preinvasive lesions.

Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, Manier ML, Olson SJ, Shah RN, Miller AN, Putnam JB, Miller YE, Franklin WA, Blot WJ, Carbone DP, Shyr Y, Caprioli RM, Massion PP.

Cancer Res. 2011 Apr 15;71(8):3009-17. doi: 10.1158/0008-5472.CAN-10-2510. Epub 2011 Apr 12.

2.

MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer.

Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, Caprioli RM.

Proteomics Clin Appl. 2008 Oct;2(10-11):1508-17. doi: 10.1002/prca.200800094. Epub 2008 Sep 10.

3.

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.

Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD.

Cancer Res. 2010 Dec 1;70(23):9937-48. doi: 10.1158/0008-5472.CAN-10-0881. Epub 2010 Nov 30.

4.

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer.

Lu M, Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR.

Clin Proteomics. 2010 Sep;6(3):93-103. Epub 2010 Sep 7.

5.

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.

Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA.

Clin Cancer Res. 2010 Oct 1;16(19):4702-10. doi: 10.1158/1078-0432.CCR-10-0939. Epub 2010 Sep 21. Review.

6.

Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer.

Lu M, Whitelegge JP, Whelan SA, He J, Saxton RE, Faull KF, Chang HR.

J Proteomics Bioinform. 2010 Jan 22;3(2):1-10.

7.

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.

Chang HR.

Cancer. 2010 Jun 15;116(12):2856-67. doi: 10.1002/cncr.25120. Review.

8.

Quantitative proteomic profiling of matched normal and tumor breast tissues.

Sutton CW, Rustogi N, Gurkan C, Scally A, Loizidou MA, Hadjisavvas A, Kyriacou K.

J Proteome Res. 2010 Aug 6;9(8):3891-902. doi: 10.1021/pr100113a.

PMID:
20560667
9.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

10.

Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue.

Röwer C, Vissers JP, Koy C, Kipping M, Hecker M, Reimer T, Gerber B, Thiesen HJ, Glocker MO.

Anal Bioanal Chem. 2009 Dec;395(8):2443-56. doi: 10.1007/s00216-009-3187-9. Epub 2009 Oct 29.

PMID:
19876624
11.

New trends in molecular biomarker discovery for breast cancer.

Radpour R, Barekati Z, Kohler C, Holzgreve W, Zhong XY.

Genet Test Mol Biomarkers. 2009 Oct;13(5):565-71. doi: 10.1089/gtmb.2009.0060. Review.

PMID:
19814613
12.

Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.

He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR.

Int J Oncol. 2009 Oct;35(4):683-92.

PMID:
19724903
13.

Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.

Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, Yu LG.

Cancer Res. 2009 Sep 1;69(17):6799-806. doi: 10.1158/0008-5472.CAN-09-1096. Epub 2009 Aug 18.

14.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS.

N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.

15.

The expression analysis of periostin in human breast cancer.

Zhang Y, Zhang G, Li J, Tao Q, Tang W.

J Surg Res. 2010 May 1;160(1):102-6. doi: 10.1016/j.jss.2008.12.042. Epub 2009 Feb 27.

PMID:
19524268
16.

Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.

Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR.

J Proteome Res. 2009 Aug;8(8):4151-60. doi: 10.1021/pr900322g.

17.

Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry.

Schulz DM, Böllner C, Thomas G, Atkinson M, Esposito I, Höfler H, Aubele M.

J Proteome Res. 2009 Jul;8(7):3430-8. doi: 10.1021/pr900071h.

PMID:
19485423
18.

The multifaceted role of periostin in tumorigenesis.

Ruan K, Bao S, Ouyang G.

Cell Mol Life Sci. 2009 Jul;66(14):2219-30. doi: 10.1007/s00018-009-0013-7. Epub 2009 Mar 24. Review.

PMID:
19308325
19.

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.

Breast Cancer Res Treat. 2010 Jan;119(2):283-93. doi: 10.1007/s10549-009-0345-x. Epub 2009 Feb 24.

PMID:
19238537
20.

Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines.

Liang X, Huuskonen J, Hajivandi M, Manzanedo R, Predki P, Amshey JR, Pope RM.

Proteomics. 2009 Jan;9(1):182-93. doi: 10.1002/pmic.200700957.

PMID:
19053080

Supplemental Content

Support Center